Literature DB >> 19015274

The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy.

George H Sakorafas1, Helmut Friess, George Peros.   

Abstract

Medullary thyroid cancer (MTC) may occur either sporadically or on a hereditary basis. Hereditary MTC may be observed with either multiple endocrine neoplasia syndromes (MEN 2A and MEN 2B) or as familial MTC (FMTC). Despite the rarity of these syndromes, early diagnosis is especially important, since MTC is a lethal disease if not promptly and appropriately treated. Recently, the development of genetic testing and direct DNA analysis allows the identification of asymptomatic patients. Surgical prophylaxis should be considered in these cases, ideally to prevent the development of MTC. During the recent decade, the concept of 'codon-directed' timing of prophylactic surgery emerged as a reasonable strategy in the management of these patients. Currently, genetic analysis offers the possibility to define genotype-phenotype correlations and to adjust the time of prophylactic surgery. Hereditary MTC is a model of genetically determined cancer in which both diagnostic and therapeutic strategies rely on the identification of specific mutations.

Entities:  

Mesh:

Year:  2008        PMID: 19015274     DOI: 10.1677/ERC-08-0098

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  10 in total

1.  Historical evolution of thyroid surgery: from the ancient times to the dawn of the 21st century.

Authors:  George H Sakorafas
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

2.  The rare intracellular RET mutation p.S891A in a Chinese Han family with familial medullary thyroid carcinoma.

Authors:  Xiao-Ping Qi; Rong-Xin Zhang; Jin-Lin Cao; Zhen-Guang Chen; Hang-Yang Jin; Ren-Rong Yang
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

3.  RET gene mutations and polymorphisms in medullary thyroid carcinomas in Indian patients.

Authors:  B P Sharma; D Saranath
Journal:  J Biosci       Date:  2011-09       Impact factor: 1.826

4.  Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience.

Authors:  Anish Jacob Cherian; Pooja Ramakant; Rekha Pai; Marie Therese Manipadam; S Elanthenral; Anuradha Chandramohan; Julie Hephzibah; David Mathew; Dhukabandhu Naik; Thomas V Paul; Simon Rajaratnam; Nihal Thomas; M J Paul; Deepak Thomas Abraham
Journal:  Indian J Surg Oncol       Date:  2017-12-08

5.  Genetic disorders of pediatric MEN2A patients in the south of Spain.

Authors:  Y Martinez-Criado; R M Fernandez; S Borrego; R Cabello; I Fernandez-Pineda
Journal:  Clin Transl Oncol       Date:  2014-03-19       Impact factor: 3.405

6.  Pediatric ethics guidelines for hereditary medullary thyroid cancer.

Authors:  M Sara Rosenthal; Douglas S Diekema
Journal:  Int J Pediatr Endocrinol       Date:  2011-03-07

7.  Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer.

Authors:  Hari Deshpande; Sanziana Roman; Jaykumar Thumar; Julie Ann Sosa
Journal:  Clin Med Insights Oncol       Date:  2011-07-20

8.  Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer.

Authors:  Hari Deshpande; Vicky Marler; Julie Ann Sosa
Journal:  Onco Targets Ther       Date:  2011-12-09       Impact factor: 4.147

9.  Parity and thyroid cancer risk: a meta-analysis of epidemiological studies.

Authors:  Jingjing Zhu; Xiao Zhu; Chao Tu; Yuan-Yuan Li; Ke-Qing Qian; Cheng Jiang; Tong-Bao Feng; Changwei Li; Guang Jian Liu; Lang Wu
Journal:  Cancer Med       Date:  2015-12-29       Impact factor: 4.452

10.  Oncogenesis of Thyroid Cancer

Authors:  Enas Younis
Journal:  Asian Pac J Cancer Prev       Date:  2017-05-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.